GenScript Partners With Tamarind Bio to Speed AI Drug Discovery Validation

GenScript Biotech Corporation and Tamarind Bio announced a strategic partnership on Tuesday to connect AI-powered molecular design with laboratory validation, giving researchers a streamlined workflow to move from computational designs to experimental testing.

The collaboration integrates Tamarind Bio's molecular design platform with GenScript's end-to-end wet-lab services, allowing researchers to submit AI-generated biological sequences directly for synthesis, expression, and testing. The companies said the workflow is designed to reduce manual handoffs between computational design and laboratory validation, helping research teams evaluate promising candidates more efficiently.

According to the announcement, GenScript's validation infrastructure can generate experimental data in as little as four days, enabling scientists to assess AI-generated molecules earlier in the drug discovery process. The company said its biologics expertise and laboratory capabilities are intended to help researchers generate higher-quality experimental datasets that can support downstream development decisions.

"AI is opening doors the industry could only imagine a few years ago," Ray Chen, President of GenScript Life Science Group, said. "But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation."

Validation Emerges as the Next Challenge

The partnership reflects a broader shift in AI-driven drug discovery as companies increasingly focus on turning computational predictions into experimentally verified results. While AI systems can rapidly generate thousands of molecular candidates, laboratory validation remains one of the most resource-intensive stages of the discovery process.

That transition from AI-generated designs to biological evidence has become a growing focus across the life sciences industry. Recent collaborations, including Chai Discovery's expanded work with Novartis on AI-enabled antibody discovery, highlight how pharmaceutical companies are investing beyond model development and into the infrastructure needed to evaluate promising candidates.

Tamarind Bio's platform provides researchers with access to more than 300 computational biology models through a no-code interface, APIs, and AI agents. Under the partnership, scientists will be able to move molecular designs generated on the platform directly into GenScript's laboratory workflow without leaving the connected environment.

"Tamarind was built to make advanced molecular design accessible to every scientist," Deniz Kavi, CEO and Co-Founder of Tamarind Bio, said. "Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever."

The collaboration also builds on GenScript's strategy of supporting AI-native drug discovery companies through laboratory validation. Earlier this year, the company partnered with Latent Labs to provide experimental testing for molecules designed using the startup's AI platform, reflecting growing demand for integrated computational and wet-lab workflows. 

The latest partnership comes as AI drug discovery continues to evolve from generating novel molecules toward producing experimental evidence that can guide development decisions. It also follows broader industry efforts to connect AI-driven discovery with downstream development, including the AI collaboration between Insilico Medicine and Bora Pharmaceuticals.